Yet another drug maker has agreed in principle to pay a stiff fine to resolve an investigation into its relationships with patient charities. The latest company to do so is the U.S. subsidiary of Lundbeck (HLUYY), a Danish drug maker that will fork over $52.6 million.

The announcement comes two years after the U.S. Attorney issued a subpoena in connection with an investigation of payments that Lundbeck made to an unspecified number of charities that provided financial assistance to patients taking various medicines (see page 50).

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy